ALNY- Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. (ALNY) has 11 insiders with recent SEC Form 4 filings, including 0 buys and 173 sells. ALNY is classified in the Biotechnology industry within the Health Care sector.
Insider Ownership
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 79.1K | $22.00M | - | |
| CFO | 58.4K | $16.24M | - | |
| VP | 29.8K | $8.28M | - | |
| VP | 23.7K | $6.59M | - | |
| Dir | 23.2K | $6.45M | - |
Activity
Buys and sells only
Transactions
10 filings
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 13, 2026 | Fitzgerald Kevin Joseph | CSO &EVP, Head Of Research | Sell | 3,800 | $367.37 | $1,395,992.00 | -0.6% | -12.9% | - | |
| Jan 12, 2026 | Garg Pushkal50 | EVP Chief R&D | Sell | 1,510 | $362.87 | $547,928.97 | -0.3% | -13.2% | - | |
| Jan 12, 2026 | Greenstreet Yvonne49 | Chief Executive Officer | Sell | 9,577 | $362.86 | $3,475,156.51 | -0.6% | -13.2% | - | |
| Jan 12, 2026 | Poulton Jeffrey V.45 | EVP, Chief Financial Officer | Sell | 2,780 | $362.87 | $1,008,765.87 | -0.2% | -13.2% | - | |
| Jan 12, 2026 | Tanguler Tolga57 | EVP, Chief Commercial Officer | Sell | 1,510 | $362.87 | $547,927.38 | -0.2% | -13.2% | - | |
| Nov 17, 2025 | Fitzgerald Kevin Joseph | CSO &EVP, Head Of Research | Sale+OE | 12,128 | $452.18 | $5,483,989.61 | -4.5% | -27.8% | - | |
| Nov 13, 2025 | Greenstreet Yvonne49 | Chief Executive Officer | Sale+OE | 25,650 | $452.75 | $11,613,003.42 | -1.8% | -29.0% | - | |
| Oct 3, 2025 | Garg Pushkal50 | EVP Chief R&D | Sell | 5,959 | $451.76 | $2,692,061.89 | -1.5% | -12.3% | - | |
| Oct 2, 2025 | Tanguler Tolga57 | EVP, Chief Commercial Officer | Sell | 1,199 | $452.50 | $542,549.41 | -0.5% | -13.7% | - | |
| Oct 2, 2025 | Fitzgerald Kevin Joseph | CSO &EVP, Head Of Research | Sell | 661 | $454.98 | $300,740.31 | -0.5% | -13.7% | - |
Page 1Next →